Elion Therapeutics Inc.
- Address
- 1 Lincoln Street Suite 2900-121
Sponsor Overview
Specializations
Invasive fungal infection research
Elion Therapeutics Inc. is focused on clinical research in suspected invasive mould infection, with interest in early treatment strategies for serious fungal disease.
- Early antifungal therapy
- Invasive mould infections
- Antifungal efficacy
- Antifungal safety
The sponsor’s research activity is centered on comparing antifungal approaches used in the initial management of patients with suspected invasive mould infection.
Systemic antifungal treatment
The clinical program includes evaluation of therapies used for systemic fungal infections, with attention to agents relevant to severe mycotic disease.
- Liposomal amphotericin B
- Voriconazole
- Comparative antifungal therapy
Research interest extends to treatment sequences used after initial antifungal management in patients at risk for invasive fungal disease.
Hospital-based infectious disease care
Elion Therapeutics’ trial activity is aligned with hospital infectious disease settings where rapid identification and treatment of suspected fungal infection are clinically important.
- Severe infection management
- Acute care antifungal use
- Specialist infectious disease treatment
The sponsor’s research landscape reflects interest in therapies used for patients requiring urgent management of suspected invasive mould infection.
Anti-infective drug development
As a pharmaceutical company, Elion Therapeutics is engaged in the clinical evaluation of anti-infective agents intended for difficult-to-treat fungal infections.
- Novel antifungal compounds
- Therapeutic comparison
- Clinical safety assessment
The company’s research focus is concentrated on therapies developed for invasive mould infection and related antifungal treatment pathways.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Phase 2 Randomized Study of EL219 Versus Liposomal Amphotericin B and Voriconazole for Early Antifungal Therapy of Suspected Invasive Mould Infections |  Belgium France Italy Spain | Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 13 sites across their trial portfolio.
Therapeutic Focus
- 1.Bacterial Infections and Mycoses1 trial180 other sponsors
Partnered Research Centres
13 centres- Address
- Ruddershove 10, 8000 Bruges
- Address
- Avenue De L'Hopital 1, 4000 Liège
- Address
- 69 Rue Du Lieutenant Colonel Prudhon, 95107 Argenteuil
- Address
- Largo Francesco Vito 1, 00168 Rome
- Address
- 100 Boulevard Du General Leclerc, 92110 Clichy
- Address
- Calle Villarroel 170, 08036 Barcelona
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Elion Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.